# A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy

> **NCT05059223** · PHASE3 · COMPLETED · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 90 (actual)

## Conditions studied

- Narcolepsy
- Cataplexy
- Excessive Daytime Sleepiness

## Interventions

- **DRUG:** AXS-12 (reboxetine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05059223
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-15
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-03-15
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05059223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05059223, "A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05059223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*